Latest & greatest articles for rivaroxaban

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on rivaroxaban or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on rivaroxaban and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for rivaroxaban

41. Unplanned pregnancy on a direct oral anticoagulant (Rivaroxaban): A warning (PubMed)

Unplanned pregnancy on a direct oral anticoagulant (Rivaroxaban): A warning Direct oral anticoagulants (DOACs or NOACs -non-vitamin K oral anticoagulants), as the name suggests, are oral anticoagulants with a direct inhibitory action either against factor X or factor II (thrombin). Pregnant women were excluded from participating in all the large trials of the DOACs and they are considered contra-indicated in pregnancy and breast feeding. We present a case of inadvertent exposure to rivaroxaban

Full Text available with Trip Pro

2015 Obstetric medicine

42. Is long-term Rivaroxaban superior to Warfarin in pulmonary embolism at 6 months?

Is long-term Rivaroxaban superior to Warfarin in pulmonary embolism at 6 months? BestBets: Is long-term Rivaroxaban superior to Warfarin in pulmonary embolism at 6 months? Is long-term Rivaroxaban superior to Warfarin in pulmonary embolism at 6 months? Report By: Chris Morgan - Medical Student Y5 Search checked by Rick Body - Consultant in Emergency Medicine Institution: University of Manchester, Manchester, UK Original institution: Manchester Royal Infirmary Date Submitted: 21st October 2015 (...) Date Completed: 21st October 2015 Last Modified: 21st October 2015 Status: Green (complete) Three Part Question In [patients with proven pulmonary embolism (PE)] is [Rivaroxaban better than warfarin] at [reducing mortality and recurrence of venous thromboembolism at 6 months]? Clinical Scenario A 52-year-old lady has presented to the Emergency Department with a suspected PE. This is confirmed by CT pulmonary angiography (CTPA). Consequently she requires anticoagulation. Hospital guidelines suggest

2015 BestBETS

43. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation (PubMed)

Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation VENTURE-AF is the first prospective randomized trial of uninterrupted rivaroxaban and vitamin K antagonists (VKAs) in patients with non-valvular atrial fibrillation (NVAF) undergoing catheter ablation (CA).Trial size was administratively set at 250, the protocol-specified target. Events were independently and blindly adjudicated. We randomly assigned 248 NVAF patients (...) to uninterrupted rivaroxaban (20 mg once-daily) or to an uninterrupted VKA prior to CA and for 4 weeks afterwards. The primary endpoint was major bleeding events after CA. Secondary endpoints included thromboembolic events (composite of stroke, systemic embolism, myocardial infarction, and vascular death) and other bleeding or procedure-attributable events. Patients were 59.5 ± 10 years of age, 71% male, 74% paroxysmal AF, and had a CHA2DS2-VASc score of 1.6. The average total heparin dose used to manage

Full Text available with Trip Pro

2015 EvidenceUpdates

44. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified Pulmonary Embolism Severity Index score from a post hoc analysis of the EINSTEIN PE study (PubMed)

Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified Pulmonary Embolism Severity Index score from a post hoc analysis of the EINSTEIN PE study The objective was to assess adverse outcomes in relation to the simplified Pulmonary Embolism Severity Index (PESI) score in patients treated with rivaroxaban or standard therapy in the phase III EINSTEIN PE study and to evaluate the utility of the simplified PESI score to identify low-risk pulmonary embolism (PE) patients.A post hoc (...) analysis of EINSTEIN PE data was performed to assess the efficacy and safety of rivaroxaban in patients with a range of simplified PESI scores. Recurrent venous thromboembolism, fatal PE, all-cause mortality, and major bleeding were stratified by simplified PESI scores of 0, 1, or ≥2 and according to treatment period at 7, 14, 30, and 90 days and at the end of the full intended treatment period.Simplified PESI scores could be calculated in 4,831 of the 4,832 randomized patients; of those, 53.6, 36.7

Full Text available with Trip Pro

2015 EvidenceUpdates

45. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in (PubMed)

Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Digoxin is a widely used drug for ventricular rate control in patients with atrial fibrillation (AF), despite a scarcity of randomised trial data. We studied the use and outcomes of digoxin in patients in the Rivaroxaban Once Daily Oral Direct

2015 Lancet

46. Rivaroxaban (Xarelto)

Rivaroxaban (Xarelto) © 2015 Thrombosis Canada Page 1 of 3 RIVAROXABAN (XARELTO ? ) OBJECTIVE: To provide an overview of the mechanism of action, licensed indications, dosing regimens and side- effects for rivaroxaban. BACKGROUND: Rivaroxaban (Xarelto ? ) is an oral factor Xa inhibitor. By binding reversibly to the active site of factor Xa, rivaroxaban attenuates thrombin generation and reduces fibrin formation. INDICATIONS: Rivaroxaban is currently licensed in Canada for: ? Thromboprophylaxis (...) thereafter. ? Rivaroxaban should not be used in patients with a CrCl 50 mL/min or 15 mg OD for those with CrCl 30-49 mL/min. MONITORING: Routine laboratory monitoring is unnecessary. Although the prothrombin time/international normalized ratio (PT/INR) and activated partial thromboplastin time (aPTT) do not provide reliable measures of rivaroxaban’s anticoagulant activity, the prothrombin time is more responsive. Anti- factor Xa assays using rivaroxaban calibrators, where available, can be used

2015 Thrombosis Interest Group of Canada

47. In nonvalvular atrial fibrillation, effects of rivaroxaban compared with warfarin did not differ by patient age (PubMed)

In nonvalvular atrial fibrillation, effects of rivaroxaban compared with warfarin did not differ by patient age 25402538 2015 04 14 2018 12 02 1539-3704 161 10 2014 Nov 18 Annals of internal medicine Ann. Intern. Med. ACP Journal Club: in nonvalvular atrial fibrillation, effects of rivaroxaban compared with warfarin did not differ by patient age. JC5 10.7326/0003-4819-161-10-201411180-02005 Rondina Matthew M eng K23 HL092161 HL NHLBI NIH HHS United States R01 AG048022 AG NIA NIH HHS United

Full Text available with Trip Pro

2014 Annals of Internal Medicine

48. Rivaroxaban 2.5 mg (Xarelto): no justification for using this anticoagulant after an acute coronary syndrome

Rivaroxaban 2.5 mg (Xarelto): no justification for using this anticoagulant after an acute coronary syndrome Prescrire IN ENGLISH - Spotlight ''Rivaroxaban 2.5 mg (Xarelto°): no justification for using this anticoagulant after an acute coronary syndrome'', 1 October 2014 {1} {1} {1} | | > > > Rivaroxaban 2.5 mg (Xarelto°): no justification for using this anticoagulant after an acute coronary syndrome Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |  (...)  |   |   |   |   |   |   |   |  Spotlight Rivaroxaban 2.5 mg (Xarelto°): no justification for using this anticoagulant after an acute coronary syndrome FEATURED REVIEW It has not been demonstrated that adding rivaroxaban to aspirin alone or to aspirin plus clopidogrel benefits patients who have had an acute coronary syndrome. The risk of serious and fatal bleeds is probably underestimated. Caution dictates that rivaroxaban should

2014 Prescrire

49. Apixaban and rivaroxaban for stroke prevention in atrial fibrillation: safety

Apixaban and rivaroxaban for stroke prevention in atrial fibrillation: safety Apixaban and rivaroxaban for stroke prevention in atrial fibrillation: safety Apixaban and rivaroxaban for stroke prevention in atrial fibrillation: safety CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Apixaban and rivaroxaban for stroke (...) prevention in atrial fibrillation: safety. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Reference List. 2014 Authors' conclusions Twenty-two systematic reviews/meta-analyses, 24 randomized controlled trials, and three non-randomized studies were identified regarding adverse events associated with the use of apixaban and rivaroxaban. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Anticoagulants; Atrial Fibrillation; Humans; Morpholines

2014 Health Technology Assessment (HTA) Database.

50. Rivaroxaban (Xarelto- Bayer Inc.) new Indication: pulmonary embolism

Rivaroxaban (Xarelto- Bayer Inc.) new Indication: pulmonary embolism Rivaroxaban (Xarelto- Bayer Inc.) new Indication: pulmonary embolism Rivaroxaban (Xarelto- Bayer Inc.) new Indication: pulmonary embolism CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Rivaroxaban (Xarelto- Bayer Inc.) new Indication: pulmonary embolism (...) . Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDEC final recommendation. 2014 Authors' conclusions CDEC recommends that rivaroxaban be listed for the treatment of VTE (DVT and PE) and prevention of recurrent DVT and PE, for a duration of up to six months. If treatment is to be extended beyond six months, the following condition must be met. Condition: A reduction in price is required if rivaroxaban is funded for a treatment duration of more than six months. Final publication

2014 Health Technology Assessment (HTA) Database.

51. Bleeding with dabigatran, rivaroxaban, apixaban: no antidote, and little clinical experience

Bleeding with dabigatran, rivaroxaban, apixaban: no antidote, and little clinical experience Prescrire IN ENGLISH - Spotlight ''Bleeding with dabigatran, rivaroxaban, apixaban: no antidote, and little clinical experience '', 1 June 2013 {1} {1} {1} | | > > > Bleeding with dabigatran, rivaroxaban, apixaban: no antidote, and little clinical experience Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |    (...) |   |   |   |  Spotlight Bleeding with dabigatran, rivaroxaban, apixaban: no antidote, and little clinical experience FEATURED REVIEW Dabigatran, rivaroxaban and apixaban are oral anticoagulants used to prevent or treat thrombosis. Difficulties in the management of bleeding weigh heavily in the balance of potential harm versus potential benefit of these drugs. Full review (5 pages) available for download by subscribers. Abstract Dabigatran, rivaroxaban and apixaban

2014 Prescrire

52. Rivaroxaban - Thromboembolic events (venous), pulmonary embolism

Rivaroxaban - Thromboembolic events (venous), pulmonary embolism Common Drug Review CDEC Meetings: October 16, 2013; January 15, 2013; March 19, 2014 Notice of Final Recommendation — March 26, 2014 Page 1 of 6 © 2014 CADTH CDEC FINAL RECOMMENDATION RIVAROXABAN (Xarelto — Bayer Inc.) New Indication: Pulmonary Embolism Recommendation: CDEC recommends that rivaroxaban be listed for the treatment of VTE (DVT and PE) and prevention of recurrent DVT and PE, for a duration of up to six months (...) . If treatment is to be extended beyond six months, the following condition must be met: Condition: ? A reduction in price is required if rivaroxaban is funded for a treatment duration of more than six months. Reason for the Recommendation: 1. In one randomized controlled trial (RCT) involving patients with acute PE (EINSTEIN-PE), rivaroxaban was reported to be non-inferior to a regimen of enoxaparin plus a vitamin K antagonist (VKA) based on the incidence of recurrent DVT, non-fatal PE, or fatal PE. Given

2014 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

53. Apixaban and Rivaroxaban for Stroke Prevention in Atrial Fibrillation

Apixaban and Rivaroxaban for Stroke Prevention in Atrial Fibrillation Title: Apixaban and Rivaroxaban for Stroke Prevention in Atrial Fibrillation: Safety DATE: 28 March 2014 RESEARCH QUESTIONS 1. What are the adverse events associated with the use of apixaban? 2. What are the adverse events associated with the use of rivaroxaban? KEY MESSAGE Twenty-two systematic reviews/meta-analyses, 24 randomized controlled trials, and three non- randomized studies were identified regarding adverse events (...) associated with the use of apixaban and rivaroxaban. METHODS A limited literature search was conducted on key resources including PubMed, The Cochrane Library (2014, Issue 3), University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. Methodological filters were applied to limit retrieval to safety data. Where possible, retrieval was limited to the human population. The search was also limited

2014 Canadian Agency for Drugs and Technologies in Health - Rapid Review

54. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation

Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation Harrington AR, Armstrong EP, Nolan PE, Malone DC Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) . Interventions The four interventions were warfarin, apixaban 5mg twice daily, dabigatran 150mg twice daily, and rivaroxaban 20mg once daily. Warfarin dose was assumed to be adjusted to achieve the patient's target international normalised ratio (INR). Location/setting USA/in-patient and out-patient care. Methods Analytical approach: A Markov model, with one-month cycles, combined the published data. The time horizon was 30 years and the authors stated that the perspective was societal. Effectiveness data

Full Text available with Trip Pro

2013 NHS Economic Evaluation Database.

55. Rivaroxaban - stroke prevention in patients with atrial fibrillation

Rivaroxaban - stroke prevention in patients with atrial fibrillation Common Drug Review CDEC Meeting – June 19, 2013 Notice of CDEC Final Recommendation – July 18, 2013 Page 1 of 6 © 2013 CADTH CDEC FINAL RECOMMENDATION RIVAROXABAN (Xarelto – Bayer Inc.) Indication: Stroke Prevention in Atrial Fibrillation Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that rivaroxaban be listed for the prevention of stroke and systemic embolism in patients with atrial fibrillation who (...) meet all of the following clinical criteria: Clinical Criteria: 1. Patients with a CHADS 2 score = 2. 2. Patients who are unable to readily achieve adequate anticoagulation with warfarin. Reasons for the Recommendation: 1. In one large, double-blind, randomized controlled trial (RCT) of patients with a CHADS 2 score of greater than or equal to 2 (ROCKET-AF), rivaroxaban was reported to be non- inferior, but not superior, to adjusted-dose warfarin, based on the incidence of stroke or systemic

2013 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

56. Meta-analysis of rivaroxaban and bleeding risk

Meta-analysis of rivaroxaban and bleeding risk Meta-analysis of rivaroxaban and bleeding risk Meta-analysis of rivaroxaban and bleeding risk Wasserlauf G, Grandi SM, Filion KB, Eisenberg MJ CRD summary This review concluded that with a decrease in fatal bleeding and no suggestion of an increase in all-cause mortality, rivaroxaban has a favourable bleeding-related safety profile. This is an appropriate conclusion but without a comparison of both efficacy and safety in these trial populations (...) it would be difficult to make clinical judgements regarding the use of rivaroxaban. Authors' objectives To compare the safety of rivaroxaban and vitamin K antagonists (VKA), with a particular focus on bleeding and mortality. Searching MEDLINE, EMBASE, CINAHL, The Cochrane Library and Science Citation Index Expanded were searched from inception to May 2012. There were no language restrictions. Search terms were reported. Unspecified clinical trial registries were searched. Conference proceedings were

2013 DARE.

57. Clinical outcomes with rivaroxaban in patients transitioned from vitamin k antagonist therapy: a subgroup analysis of a randomized trial. (PubMed)

Clinical outcomes with rivaroxaban in patients transitioned from vitamin k antagonist therapy: a subgroup analysis of a randomized trial. In ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation), a large randomized, clinical trial, rivaroxaban was noninferior to warfarin in preventing stroke or systemic embolism in patients with atrial fibrillation.To determine the efficacy (...) and safety of rivaroxaban compared with warfarin among vitamin K antagonist (VKA)-naive and VKA-experienced patients.Prespecified subgroup analysis. (ClinicalTrials.gov: NCT00403767).Global.14,264 persons with atrial fibrillation.Interaction of the relative treatment effect of rivaroxaban and warfarin on stroke or systemic embolism among VKA-naive and VKA-experienced patients.Overall, 7897 (55.4%) patients were VKA-experienced and 6367 (44.6%) were VKA-naive. The effect of rivaroxaban versus warfarin

2013 Annals of Internal Medicine

58. Meta-Analysis of Rivaroxaban and Bleeding Risk (PubMed)

Meta-Analysis of Rivaroxaban and Bleeding Risk Rivaroxaban, a factor Xa inhibitor, is a new oral anticoagulant that has been developed as an alternative to vitamin K antagonists. However, its safety remains unclear. Reported randomized controlled trials comparing the safety of rivaroxaban with that of vitamin K antagonists (warfarin, acenocoumarol, phenprocoumon, and fluindione) were systematically searched. Inclusion was restricted to studies of ≥30 days' treatment duration. Safety end points (...) examined included major and clinically relevant nonmajor bleeding, as well as mortality. Data were pooled across randomized controlled trials using random-effects meta-analysis models. Five randomized controlled trials including 23,063 patients that met the inclusion criteria were identified. Patients received treatment for nonvalvular atrial fibrillation (n = 14,264), deep vein thrombosis (n = 3,967), or acute symptomatic pulmonary embolism (n = 4,832). Overall, rivaroxaban was not associated

2013 EvidenceUpdates

59. Randomised controlled trial: Oral treatment of acute pulmonary embolism with a fixed dose of rivaroxaban is non-inferior to standard treatment

Randomised controlled trial: Oral treatment of acute pulmonary embolism with a fixed dose of rivaroxaban is non-inferior to standard treatment Oral treatment of acute pulmonary embolism with a fixed dose of rivaroxaban is non-inferior to standard treatment | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our (...) . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Oral treatment of acute pulmonary embolism with a fixed dose of rivaroxaban is non-inferior to standard treatment Article Text

2013 Evidence-Based Medicine (Requires free registration)

60. New oral anticoagulants apixaban (Eliquis?), dabigatran (Pradaxa) and rivaroxaban (Xarelto?)

New oral anticoagulants apixaban (Eliquis?), dabigatran (Pradaxa) and rivaroxaban (Xarelto?) New oral anticoagulants apixaban (Eliquis▼), dabigatran (Pradaxa) and rivaroxaban (Xarelto▼) - GOV.UK GOV.UK uses cookies to make the site simpler. or Search New oral anticoagulants apixaban (Eliquis▼), dabigatran (Pradaxa) and rivaroxaban (Xarelto▼) Risk of serious haemorrhage—clarified contraindications apply to all 3 medicines. Published 11 December 2014 From: Therapeutic area: Contents Article (...) , direct inhibitor of free thrombin, fibrin-bound thrombin and thrombin-induced platelet aggregation. Apixaban (Eliquis ▼) and rivaroxaban (Xarelto ▼) are direct, highly selective, orally active inhibitors of activated factor X (factor Xa). All 3 new oral anticoagulants are licensed for: prevention of venous thromboembolic events in adults who have had elective total hip-replacement or knee-replacement surgery prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation

2013 MHRA Drug Safety Update